Parameter
| Biomarker | EphA2 | Full name | Ephrin type-A receptor 2 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prediction of chemotherapy resistance | ||
| Disease | Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Serum secrete body separation + immunoassay () | ||
| Pathobiological Mechanisms | Ephrin type A receptor 2, by participating in tumor cells of epithelial mesenchymal (EMT) and signaling pathways that control, its expression is associated with gemcitabine resistance | ||||
| Clinical Availability Status | Clinical research phase: it is used to predict the response to chemotherapy and guide the adjustment of treatment regimens | ||||
| Notes and Dynamics | Exosome-derived EphA2 can be used as a minimally invasive predictive marker, and its high expression indicates an increased risk of chemotherapy resistance | ||||